The World Has No Idea What's Coming

The next frontier of cancer treatment... The world has no idea what's coming... The 'bottom is (probably) in' checklist continues... Simple technical analysis... Beware of death crosses... Don't fight the 200-day moving average... [Stansberry Research Logo] Delivering World-Class Financial Research Since 1999 [Stansberry Digest] The next frontier of cancer treatment... The world has no idea what's coming... The 'bottom is (probably) in' checklist continues... Simple technical analysis... Beware of death crosses... Don't fight the 200-day moving average... --------------------------------------------------------------- Most years, cancer and heart disease are the undeniable top killers of Americans... I (Dave Lashmet) say "most years" because during the COVID-19 pandemic, a third cause of death unfortunately made it into the discussion. In two years, COVID killed a million Americans – and these are all considered "excess deaths." This was about a million more people than were expected to die in the same span. Thanks to vaccines – and a highly effective new pill from Pfizer called Paxlovid – as a country, we've greatly reduced the threat from COVID-19. But the pandemic brought on all kinds of unimagined consequences... and related risks linger. Today, I want to talk about one of them... and the developments unfolding right now to help create a potentially life-changing solution. Ten million fewer people got screened for cancer in 2020... In the early months of the pandemic, screening facilities were temporarily closed and many folks were afraid to go to the hospitals – if they were even open for non-emergency visits. Folks were scared off or prevented from getting regular checkups. According to the National Cancer Institute ("NCI"), nearly 10 million screening tests that normally would have taken place in the United States in 2020 didn't happen. But cancer doesn't go away because people stop looking for it. It's mostly a disease of old age, but it strikes smokers and sunbathers, too. Plus, some cancers are driven by viruses, genetics, or other risk factors. According to the NCI... These missed screenings, many experts worry, could potentially lead to cancers being diagnosed at a more advanced stage and, ultimately, to more people dying from cancer. The first, best way to protect yourself is to screen for cancer... This includes looking for bumps and lumps and submitting stool tests. For example... despite some headlines that made the rounds just this past weekend, colonoscopies do cut the chances of developing colon cancer and the rate of dying from it by 50%. This is in line with everything we know about medical treatment. Tests for traces of blood and polyps are established screening tools. But today, I want to introduce you to the next frontier of cancer screening – and treatment... Two newer tools on the cutting edge of science and medicine are starting to save lives. That's good news for tens of millions of people, of course – and for investors who know about what's going on with these biotech developments. Let me explain... The first new cancer screening tool is using "machine learning" as a sort of artificial intelligence to look for cancers. This process uses MRI machines. You see, an MRI (which stands for magnetic resonance imaging) doesn't give you images in color... It's all based on magnets, so the images you see are all shades of gray, which get collected and filed as numbers. Guess what's really good at sorting through lots of numbers... If you said "a computer," then you're on to something... As you may know, computer math-crunching capabilities double every two years... what's called Moore's Law. But you might not know that MRIs have been widely available for only a couple of decades. And at first, they couldn't find anything inside you that was smaller than a ping-pong ball. Today, MRIs can see something measuring just one-twentieth of an inch in every direction... like the ball in a ball-point pen. So, an MRI has a lot more data now – and because it's all shades of grey, a computer can see when the numbers (marking denseness) are different. Finding the 'crab legs'... It's hard for an MRI to look at and help identify a brain tumor, because brain cells all interconnect with threads to each other. Fortunately, there's a cheat code: You can add a magnetic chemical element – gadolinium – and see the blood vessels in the brain light up on an MRI. Cancer is called cancer because it's like a crab. Basically, a tumor's quest to grow has to be fueled by new blood vessels, which circle the tumor like crab legs. So when you find "crab legs," you can find a brain tumor. Then you can cut it out, sparing the rest of the brain. The second big innovation is scanning the genetic code of a cancer tumor... This helps doctors see if the tumor is ripe for targeted therapy. For example, there's a mutation called the Philadelphia chromosome, which creates a new and unnatural kind of protein. And we now have a drug to hit that. In early trials, 99% of patients had a complete response to this drug, called Gleevec. That meant their tumors disappeared. That's the promise of targeted therapy. Alas, not every cancer has such a ripe target. In fact, most tumors don't. But because the effects of targeted therapy can be so profound, it makes sense to check... Of course, the economics matter... When it cost a million dollars to screen a genetic code, this was impossible. Today, though, screening costs $600. Most of us are insured. But even if you paid in cash, it's worth $600 to find out if your cancer is easily treatable, right? It can add months or years to your life. Now, there are drugs that work even better than targeted therapies... Cancers can mutate – and they generally do – to avoid the targeted therapy. Inside a tumor, that's survival of the fittest. All the cells that by chance show less target (or none) through genetic screening are more likely to survive through mutations. So, over time, targeted therapy drugs stop working. This leads me to the next frontier of cancer treatment... I am seeing another exciting new approach to treating cancer... one that can kill a tumor and keep it from coming back. And how this technology works is still emerging... It's well-known, but it's also cutting-edge and fast-developing. In fact, in less than two weeks, a major announcement will likely make for big headlines and could force a wave of money into a handful of mostly unknown companies. I explain both parts of this particular new cancer-treatment strategy in a new presentation I just put together. I talk with my colleague and Stansberry NewsWire editor C. Scott Garliss about all the details [here](. Note, I'm not a doctor. If anything, I approach this field like a patient: I like highly effective treatments and no side effects... not scorched-earth medicine. And I also like investment opportunities... And new treatments that win approval from the U.S. Food and Drug Administration ("FDA") save lives – and generate strong financial returns. The select few companies that hold exclusive patents related to this new treatment strategy could soon be worth billions of dollars... and lead to gains of up to 400% or more, no matter what's happening in the market. This scenario could lead to the biggest gains anywhere in the market the rest of this year. But you must act now to get on board for the greatest potential upside... In less than two weeks, when industry leaders convene at an important conference, the news will start spreading. As I told Scott in our discussion... The world has no idea what's coming yet. I dug and found the exact room this announcement will be made in. No one waits to reveal their data in a venue – that seats thousands – unless they have major news... Think about it... If you had a choice to just publish your research in a journal... or be cheered on by 5,000 peers at one of the biggest conferences in the world... which would you choose? Especially a conference that specializes in treatments for one of the world's deadliest diseases you're trying to treat. My Stansberry Venture Technology subscribers have just received the details, but they're about the only ones that have them... outside of the small number of biotech executives and researchers familiar with the new treatments. If you want to get the latest about this story... what I expect to unfold soon... and the details about this potentially life-changing breakthrough in cancer treatment, [click here for more right now](. Moving on, here's the next item in the 'bottom is (probably) in' checklist... We thank Dave for his report today, and I (Corey McLaughlin) encourage folks to hear what he has to say about potentially one of the biggest breakthroughs we've ever seen in medicine... Switching gears, we'll close things out today by continuing to explore my "bottom is (probably) in" checklist with item No. 4... which is a simple and straightforward "technical" analysis of the U.S. benchmark S&P 500 Index. Before we get to the details, though, here's is quick refresher... As we showed last week, items one through three on my list have not suggested a bottom for U.S. stocks yet. The story remains the same today. [Market "breadth"]( has weakened a bit... [The U.S. dollar]( is still getting relatively stronger... and bond yields continue to rise, with short-term yields remaining higher than longer-term yields, meaning [the "yield curve"]( hasn't gotten any less inverted. Today, the 10-year U.S. Treasury yield briefly traded above 4% for the first time since 2010. Meanwhile, a 2-year note is yielding 4.3%. Wild times. For today's analysis, we're going to simply look at the price action of the S&P 500. After all, if you're trying to find a bottom in U.S. stocks, you want to look at the broad index that represents the largest publicly traded American businesses. You can't know if 'a bottom is here' if you're not actually looking at prices... To do this, we'll apply two of the simplest technical indicators to the S&P 500... a 200-day moving average (200-DMA) and 50-day moving average (50-DMA). They are what they sound like: the average closing price of a particular asset, or index in this case, from the previous 200 or 50 days. Over time, these averages drawn on a chart illustrate the long- and short-term trends of price action, respectively. Here's a one-year chart of the S&P 500 with its 200-DMA and 50-DMA... I like to look at this chart at least once a day, and often with various time frames. It reminds me what's actually happening with U.S. stocks... as opposed to what I might be hearing or seeing from the firehose of information that is available in today's world. Doing this grounds me in reality. Today, for example, you'll see the benchmark for U.S. stocks is... 1. In a downtrend – and has been all year 2. Making new lows for the year 3. Trading below its 200-DMA (and has been since April) 4. Trading below its 50-DMA That's not bullish. This is a telling objective analysis from one simple chart. It tells you the general direction of the market, provides important context (that it's making new lows), and includes a look at relative strength (with the index's place relative to its long- and short-term trends). And it takes about one second to do... Today this analysis is particularly timely... With a slight drop today, the S&P 500 matched its most recent low from two weeks ago – which was just below its previous lows made in June. In plain English, the trend for U.S. stocks is still down, and has been going lower... (Note, this doesn't mean all stocks or assets in the investable universe are going down, but that the S&P 500 is trending that way.) We could get into various reasons about why, like nervousness about the next "official" inflation reading coming later this week and a potentially terrible earnings season ahead. But the point is, price action is already warning to look out below. You can learn a lot more from this one chart, too... For instance, you can also see that the S&P 500's 50-DMA crossed below the 200-DMA in March, signaling that something was potentially amiss... the short-term trend was breaking below the long-term. Some analysts and financial-headline writers call this a "death cross." It doesn't always mean the "death" of an uptrend or the start of a severe downtrend or bear market. But this signal does tell me something like that could happen. In short, beware of death crosses when you see them. And look at this summer's "bear market rally"... It ended right when the S&P 500 hit its 200-DMA in mid-August. That's not a coincidence. It's a sign of what technical analysts call "resistance," a level where folks tend to sell and there aren't enough buyers anymore. Prices fall... The opposite of "resistance" is "support," as our colleague and DailyWealth Trader editor Chris Igou frequently [explains to his subscribers](... Support is a level at which folks tend to buy an asset and prices often stop falling. It's an obstacle for falling prices. Resistance is a level at which folks tend to sell and prices often stop rising. It's an obstacle for rising prices. Either way, if an asset breaks through support or resistance, it will often continue to move in that same direction. This was true when the S&P 500 busted through its 50-DMA in July en route to butting up against its 200-DMA in August... The short-term move indicated that short-term resistance wasn't very strong... and tells me that we could possibly see strong short-term rally behavior again down the road. Similarly, if you want to see a bottom for U.S. stocks, you're looking for support, in technical terms. So far, we have not seen it, but we'll keep watching... In DailyWealth Trader, Chris uses technical analysis in his trading strategy, much like our Ten Stock Trader editor Greg Diamond does every day in recommending his trades to subscribers. If you want to learn much more, I suggest following their expert work. I do. In the meantime, you can do this simple kind of analysis, too... Subscribers can apply moving averages and many other technical indicators to the S&P 500, or thousands of stocks and exchange-traded funds by pulling up their charts on the new [StansberryResearch.com]( clicking the "Tools" tab, then "Stansberry Indicators," and going from there. Now, some folks dismiss any kind of technical analysis as some kind of hocus-pocus. I get it. Simply put, technical analysis focuses on price behavior, patterns, and history in various forms, depending on what indicators you are using. It's the opposite of "fundamental analysis" about a company's earnings, valuation, or anything like that. The point of technical analysis is that you can apply the same set of indicators to anything that trades in the market... be it the S&P 500, oil prices, bitcoin, or coffee beans. For most of my life, I didn't even know this sort of analysis existed. But I came to understand that honest technical analysts have good reasons and explanations for what might happen – as opposed to claiming what will happen based on glorified hunches, like many other people do. And I became a believer... Technical analysis is a great tool to have in the investing toolbox. And once I understood that a lot of the Wall Street firms and institutional investors use trading algorithms that make "buy" or "sell" decisions based on technical indicators like moving averages, that only made me want to pay attention even more... Our colleague and Stansberry NewsWire editor C. Scott Garliss, who Dave introduced earlier today, spent 20 years working on Wall Street before joining our company. And he [shared more detail on the use of trading algorithms back in January](. At the time, there was a "big fight taking place" at the 200-DMA of the S&P 500. So as we explore the depths of this market for a bottom, this simple technical analysis is an important part of the search. Tomorrow, I will share another one... this time tracking the market's fundamentals. 'Now Is Not the Time to Be a Hero' On this week's Stansberry Investor Hour, Dan Ferris welcomes back Mitchel Krause, founder of Other Side Asset Management. Together, they take a stroll down memory lane to the spring of 2022 and remind folks how much the Federal Reserve actually did to "rescue" markets... [Click here]( to listen to this episode right now. And to catch all of the videos and podcasts from the Stansberry Research team, be sure to [visit our Stansberry Investor platform]( anytime. --------------------------------------------------------------- Recommended Links: [MAJOR PATENT ALERT: October 23, 2022]( A major announcement this month could force a wave of money into THREE companies. Their exclusive patents could soon be worth up to $150 billion... and lead to multiple gains up to 400%-plus no matter what's happening in the market. [Click here for the breaking story](. --------------------------------------------------------------- [Get Your Money Out of U.S. Banks Immediately]( A historic financial reset in 2023 could soon result in a run on the banks. Get out of cash and into a new vehicle 50 years in the making. [Find the full details here](. --------------------------------------------------------------- New 52-week highs (as of 10/10/22): Northrop Grumman (NOC) and short position in iShares U.S. Real Estate Fund (IYR). In today's mailbag, feedback on [yesterday's Digest]( and mail... Do you have a comment or question? As always, e-mail us at feedback@stansberryresearch.com. "Corey, Great Digest. Often I find it more challenging to stick with a good decision rather than succumb to market mania. Having a plan helps, but nonetheless, there are always a plethora of temptations. It helps that you, Doc, and Greg are voices of reason. "The rule of thumb that most often saves me from making a mistake is 'until the Fed officially signals a rate decrease, don't buy on the way to the bottom, buy on the way back up' (I'll leave it to you to tell us when the bottom is in)." – Paid-up subscriber Bill B. "To give solace to those who think they have lost 8% this year by being in cash, [they] haven't looked on the bright side. With the U.S. currency up 18% to 20% this year [relative to other global currencies] those dollar holders are up big. Go spend those dollars, they go further. Just saying." – Paid-up subscriber Bill M. All the best, Corey McLaughlin and Dave Lashmet Baltimore, Maryland and Bainbridge Island, Washington October 11, 2022 --------------------------------------------------------------- Stansberry Research Top 10 Open Recommendations Top 10 highest-returning open positions across all Stansberry Research portfolios Stock Buy Date Return Publication Analyst MSFT Microsoft 11/11/10 817.8% Retirement Millionaire Doc ADP Automatic Data 10/09/08 810.5% Extreme Value Ferris MSFT Microsoft 02/10/12 700.8% Stansberry's Investment Advisory Porter HSY Hershey 12/07/07 532.1% Stansberry's Investment Advisory Porter ETH/USD Ethereum 02/21/20 473.4% Stansberry Innovations Report Wade AFG American Financial 10/12/12 407.8% Stansberry's Investment Advisory Porter WRB W.R. Berkley 03/16/12 378.1% Stansberry's Investment Advisory Porter BRK.B Berkshire Hathaway 04/01/09 373.3% Retirement Millionaire Doc TPL Texas Pacific Land 11/05/20 306.7% Stansberry's Investment Advisory Porter FSMEX Fidelity Sel Med 09/03/08 282.1% Retirement Millionaire Doc Please note: Securities appearing in the Top 10 are not necessarily recommended buys at current prices. The list reflects the best-performing positions currently in the model portfolio of any Stansberry Research publication. The buy date reflects when the editor recommended the investment in the listed publication, and the return shows its performance since that date. To learn if a security is still a recommended buy today, you must be a subscriber to that publication and refer to the most recent portfolio. --------------------------------------------------------------- Top 10 Totals 5 Stansberry's Investment Advisory Porter 3 Retirement Millionaire Doc 1 Extreme Value Ferris 1 Stansberry Innovations Report Wade --------------------------------------------------------------- Top 5 Crypto Capital Open Recommendations Top 5 highest-returning open positions in the Crypto Capital model portfolio Stock Buy Date Return Publication Analyst ONE-USD Harmony 12/16/19 1,146.6% Crypto Capital Wade ETH/USD Ethereum 12/07/18 1,134.0% Crypto Capital Wade POLY/USD Polymath 05/19/20 1,087.6% Crypto Capital Wade MATIC/USD Polygon 02/25/21 840.2% Crypto Capital Wade BTC/USD Bitcoin 11/27/18 409.3% Crypto Capital Wade Please note: Securities appearing in the Top 5 are not necessarily recommended buys at current prices. The list reflects the best-performing positions currently in the Crypto Capital model portfolio. The buy date reflects when the recommendation was made, and the return shows its performance since that date. To learn if it's still a recommended buy today, you must be a subscriber and refer to the most recent portfolio. --------------------------------------------------------------- Stansberry Research Hall of Fame Top 10 all-time, highest-returning closed positions across all Stansberry portfolios Investment Symbol Duration Gain Publication Analyst Nvidia^* NVDA 5.96 years 1,466% Venture Tech. Lashmet Band Protocol crypto 0.32 years 1,169% Crypto Capital Wade Terra crypto 0.41 years 1,164% Crypto Capital Wade Inovio Pharma.^ INO 1.01 years 1,139% Venture Tech. Lashmet Seabridge Gold^ SA 4.20 years 995% Sjug Conf. Sjuggerud Frontier crypto 0.08 years 978% Crypto Capital Wade Binance Coin crypto 1.78 years 963% Crypto Capital Wade Nvidia^* NVDA 4.12 years 777% Venture Tech. Lashmet Intellia Therapeutics NTLA 1.95 years 775% Amer. Moonshots Root Rite Aid 8.5% bond 4.97 years 773% True Income Williams ^ These gains occurred with a partial position in the respective stocks. * The two partial positions in Nvidia were part of a single recommendation. Editor Dave Lashmet closed the first leg of the position in November 2016 for a gain of about 108%. Then, he closed the second leg in July 2020 for a 777% return. And finally, in May 2022, he booked a 1,466% return on the final leg. Subscribers who followed his advice on Nvidia could've recorded a total weighted average gain of more than 600%. You have received this e-mail as part of your subscription to Stansberry Digest. If you no longer want to receive e-mails from Stansberry Digest [click here](. Published by Stansberry Research. You’re receiving this e-mail at {EMAIL}. Stansberry Research welcomes comments or suggestions at feedback@stansberryresearch.com. This address is for feedback only. For questions about your account or to speak with customer service, call 888-261-2693 (U.S.) or 443-839-0986 (international) Monday-Friday, 9 a.m.-5 p.m. Eastern time. Or e-mail info@stansberrycustomerservice.com. Please note: The law prohibits us from giving personalized investment advice. © 2022 Stansberry Research. All rights reserved. Any reproduction, copying, or redistribution, in whole or in part, is prohibited without written permission from Stansberry Research, 1125 N Charles St, Baltimore, MD 21201 or [www.stansberryresearch.com](. Any brokers mentioned constitute a partial list of available brokers and is for your information only. Stansberry Research does not recommend or endorse any brokers, dealers, or investment advisors. Stansberry Research forbids its writers from having a financial interest in any security they recommend to our subscribers. All employees of Stansberry Research (and affiliated companies) must wait 24 hours after an investment recommendation is published online – or 72 hours after a direct mail publication is sent – before acting on that recommendation. This work is based on SEC filings, current events, interviews, corporate press releases, and what we've learned as financial journalists. It may contain errors, and you shouldn't make any investment decision based solely on what you read here. It's your money and your responsibility.